3CG-38853-84409
3 vaccinations
1 coded response
11 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 630 / MO
- Registered
- 2021-10-24
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-23
Dose 1 — Pfizer-BioNTech
-
2021-01-14
Dose 2 — Pfizer-BioNTech
-
2021-10-20
Dose 3 — Pfizer-BioNTech
-
2021-10-24
Registered in v-safe
- 2021-10-24
- 2021-10-25
- 2021-10-26
- 2021-10-29
- 2021-11-05
- 2021-11-11
- 2021-11-17
- 2021-11-26
-
2021-12-01
Survey response — day 42, dose 3MedDRA: Oropharyngeal pain, Rhinorrhoea — Feeling: GoodFree text: Runny nose and sore throatMedDRA releases: 2024-11 · check-in free text available
- 2022-01-19
- 2022-04-25
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-23 | Pfizer-BioNTech | No |
| 2 | 2021-01-14 | Pfizer-BioNTech | No |
| 3 | 2021-10-20 | Pfizer-BioNTech | No |
Free text
Release 10 — day 42, dose 3
Symptoms: Runny nose and sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release